First Tracks Biotherapeutics (TRAX) PT Raised to $55 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TRAX Hot Sheet
Price: $46.34 --0%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 21 | New: 12
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 21 | New: 12
Join SI Premium – FREE
Wells Fargo analyst Derek Archila raised the price target on First Tracks Biotherapeutics (NASDAQ: TRAX) to $55.00 (from $30.00) while maintaining a Overweight rating.
You May Also Be Interested In
- First Tracks Biotherapeutics (TRAX) PT Raised to $110 at Guggenheim, Stays Top Pick
- Booking Holdings (BKNG) PT Lowered to $150 at Cantor Fitzgerald
- First Tracks Biotherapeutics, Inc. (TRAX) Misses Q3 EPS by 88c
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
